» Articles » PMID: 38554241

Skin Color Reporting in Squamous Cell Carcinoma-related Randomized Controlled Trials in Top Dermatology Journals: a Systematic Review

Overview
Specialty Dermatology
Date 2024 Mar 30
PMID 38554241
Authors
Affiliations
Soon will be listed here.
Abstract

The objectives are to determine the frequency that skin color is reported in randomized controlled trials (RCTs) involving squamous cell carcinoma (SCC) detection and treatment in leading dermatology journals. A systematic review of RCTs involving SCC was conducted among the top ten most impactful dermatology journals from inception to July 10th, 2023. Studies were included if they reviewed the treatment, prevention, or detection of SCC, involved patients directly and were classified as traditional RCTs. Studies were considered positive for reporting SOC if there was any demographic data in the methods or results of the following terms: Fitzpatrick scale, race, ethnicity, sunburn tendency, or skin of color. Of the 39 studies which were identified, 23 reported data related to skin color data (59.0%). White individuals were the most reported in these studies (56.5%). Subgroup analysis was conducted, and no statistical significance was found for study location, year of publication, or funding source. Skin color impacts skin cancer detection, predominant location of tumors, and recurrence. Less than 60% of high-quality RCTs related to SCC in top global dermatology journals included skin color among the demographic traits of study participants. Subgroup analysis demonstrated no improvement in reporting over the past 2 decades. Further research is needed to understand the reason for low skin color reporting rates among SCC-related RCTs and the impact this has on society.

Citing Articles

Shades of evidence: a review of skin color reporting in melanoma-related randomized controlled trials.

Curtis D, Salmen N, Baumann A, Busby J, Brodell R Arch Dermatol Res. 2025; 317(1):262.

PMID: 39821404 PMC: 11739269. DOI: 10.1007/s00403-025-03793-z.


Skin color reporting in basal cell carcinoma-related randomized controlled trials in top dermatology journals: a systematic review.

Salmen N, Curtis D, Baumann A, Willets J, Brodell R Arch Dermatol Res. 2024; 316(7):451.

PMID: 38967663 PMC: 11226525. DOI: 10.1007/s00403-024-03187-7.

References
1.
Waldman A, Schmults C . Cutaneous Squamous Cell Carcinoma. Hematol Oncol Clin North Am. 2018; 33(1):1-12. DOI: 10.1016/j.hoc.2018.08.001. View

2.
Karia P, Han J, Schmults C . Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol. 2013; 68(6):957-66. DOI: 10.1016/j.jaad.2012.11.037. View

3.
Glass A, Hoover R . The emerging epidemic of melanoma and squamous cell skin cancer. JAMA. 1989; 262(15):2097-100. View

4.
Chang M, Azin M, Demehri S . Cutaneous Squamous Cell Carcinoma: The Frontier of Cancer Immunoprevention. Annu Rev Pathol. 2022; 17:101-119. DOI: 10.1146/annurev-pathol-042320-120056. View

5.
Kallini J, Hamed N, Khachemoune A . Squamous cell carcinoma of the skin: epidemiology, classification, management, and novel trends. Int J Dermatol. 2014; 54(2):130-40. DOI: 10.1111/ijd.12553. View